What is SPRAVATO® (esketamine) CIII nasal spray?
SPRAVATO® is a prescription medicine, used along with an antidepressant taken by mouth to treat:
• Adults with treatment-resistant depression (TRD)
• Depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions
SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe or effective as an anesthetic medicine.
It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.
It is not known if SPRAVATO® is safe and effective in children.
An oral antidepressant alone may not be the best option
If you’ve taken two or more oral antidepressants and still experience symptoms of depression, you might have treatment-resistant depression (TRD)
1 in 3 people did not experience a reduction in their depressive symptoms when taking oral antidepressants alone.
After inadequate response to 2 oral antidepressants, the chance to see benefit from a third oral antidepressant alone dropped to 14%.
SPRAVATO® offers a different approach
SPRAVATO® is the only nasal spray treatment indicated for people who’ve taken two or more oral antidepressants and still experience symptoms of depression, or TRD.
SPRAVATO® is an N-methyl-D-aspartate (NMDA) receptor antagonist that is believed to work differently by acting on a pathway in the brain where glutamate, a brain chemical, works with other brain chemicals to balance well-being and depression.
The exact way SPRAVATO® works is not fully understood.
SPRAVATO® Dosing Schedule
-
SPRAVATO® is administered twice a week for the first four weeks.
-
After the first four weeks, you and your healthcare provider will discuss and determine if treatment should be continued, the dose, and how often you’ll receive SPRAVATO®.
Serious side effects of SPRAVATO® include feeling sleepy (sedation or loss of consciousness); feeling disconnected from yourself, your thoughts, feelings, and things around you (dissociation); breathing problems (respiratory depression and respiratory arrest); abuse and misuses; increased risk of suicidal thoughts and behavior; increased blood pressure; problems with thinking clearly and bladder problems.
The most common side effects during and after taking SPRAVATO® include:
- Dissociation
- Dizziness
- Nausea
- Sedation
- Spinning sensation
- Numbness
- Feeling anxious
- Lack of energy
- Increased blood pressure
- Vomiting
- Feeling drunk
- Feeling very happy or excited
Why SPRAVATO®?
Frequently Asked Questions About SPRAVATO®
How has SPRAVATO® helped patients with TRD?
Scan the QR code below to watch as real patients with TRD share their stories.
Has the effect of treatment with SPRAVATO® been studied?
The SPRAVATO® short-term study lasted four weeks
-
In a short-term study, more patients using SPRAVATO® plus oral antidepressant demonstrated rapid and superior reduction in depressive symptoms at four weeks compared to those who received placebo plus an oral antidepressant
-
Most of the reduction in depressive symptoms was seen at 24 hours
-
Between 24 hours and four weeks, both groups continued to improve; the difference in improvement between the groups remained but did not appear to increase through four weeks
SPRAVATO® was also studied in a long-term maintenance-of-effect trial
-
The trial compared patients who stayed on SPRAVATO® and oral antidepressant to placebo and oral antidepressant long term
-
Patients who stayed on SPRAVATO® were less likely to experience a return of depressive symptoms (known as relapse) compared to those who stopped therapy